SOURCE: Industrial Info Resources

August 20, 2007 06:58 ET

No More Rumors: Amgen Slashing $2 Billion Capital Investments and 2,500 Employees, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - August 20, 2007) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- The rumors started multiplying on industry insider websites earlier this year, all hinting that Big Bio Amgen (NASDAQ:AMGN) (South San Francisco, California) was preparing to initiate massive layoffs and would scrap a number of major capital projects. The early signs were there, including putting its highly vaunted $1 billion Cork, Ireland project on ice, or in the company's words "...rescoping..." But they ceased being rumors as the questions moved from the bloggers to Amgen's announcement that in response to the twin dragons of poor sales and health alarms surrounding its anemia drugs, Aranesp and EPOGEN, it would shed 12-14% of its employees and cancel nearly $2 billion worth of capital projects. It is a page out of Big Pharma's playbook that the biggest biotech company in the world did not expect or desire to read.

For details, including a list of Amgen projects, view the entire article by subscribing to Industrial Info's Premium Industrial News at www.industrialinfo.com.

Industrial Info Resources (IIR) provides marketing communication services ranging from industrial database solutions to market forecasting, custom analytics, and specialty promotions that support high-level image campaigns. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.

Contact Information

  • Contact:
    Joe Govreau
    713-783-5147